Exercise Decreases Anti-Müllerian Hormone in Anovulatory Overweight Women with Polycystic Ovary Syndrome – A Pilot Study
- 11 October 2011
- journal article
- research article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 43 (13), 977-979
- https://doi.org/10.1055/s-0031-1291208
Abstract
Polycystic ovary syndrome (PCOS) is a common condition in women associated with menstrual irregularity and anovulation. While obesity worsens and weight loss or exercise improves reproduction function in PCOS, the mechanism for this is unclear. The aim of this study was to examine the effect of exercise on ovarian hormones [anti-Müllerian hormone (AMH)] and menstrual and ovulatory function in women with and without PCOS. Overweight women with (n=7) and without (n=8) PCOS of comparable age, weight and BMI undertook a 12-week intensified endurance exercise training program (1 h 3 times/week) with no structured energy restriction. Primary outcomes were AMH, ovulation (weekly urinary pregnanediol) and menstrual regularity. Secondary outcomes were insulin resistance (euglycemic hyperinsulinemic clamp) and body composition (computed tomography and dual X-ray absorptiometry). Exercise decreased BMI, total and android fat mass and improved insulin sensitivity for all women. AMH was significantly higher in women with PCOS compared to controls before (p<0.001) and after exercise (p=0.001). There was a significant interaction between AMH changes with exercise and PCOS status (p=0.007) such that women without PCOS had no change in AMH (+1.4±5.2 pmol/l, p=0.48) while women with PCOS had a decrease in AMH (− 13.2±11.7 pmol/l, p=0.025). Exercise is associated with improvements in ovarian hormones in women with abnormal ovarian function. This suggests that mechanisms associated with ovarian dysfunction can be improved by exercise in PCOS.This publication has 10 references indexed in Scilit:
- Effects of Exercise on Insulin Resistance and Body Composition in Overweight and Obese Women with and without Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2011
- The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive ageGynecological Endocrinology, 2010
- Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high?Reproduction, 2010
- The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairmentHuman Reproduction, 2009
- Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndromeHuman Reproduction, 2009
- Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot studyHuman Reproduction, 2007
- The Use of Anti-Müllerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2007
- Serum anti-Mullerian hormone throughout the human menstrual cycleHuman Reproduction, 2006
- Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndromeHuman Reproduction, 2005
- Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatmentFertility and Sterility, 2005